We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

FBXW7 L443F - Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FBXW7
Variant L443F
Impact List missense
Protein Effect loss of function - predicted
Gene Variant Descriptions FBXW7 L443F lies within WD repeat 2 of the Fbxw7 protein (UniProt.org). L443F induces degradation of Mcl-1 and Braf similar to wild-type Fbxw7 in culture but fails to induce Cyclin E degradation (PMID: 32907612) and results in a loss of NICD degradation leading to increased Notch transcriptional activity in a reporter assay (PMID: 27247421), and therefore, is predicted to lead to a loss of Fbxw7 protein function.
Associated Drug Resistance
Category Variants Paths

FBXW7 mutant FBXW7 inact mut FBXW7 L443F

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_033632.3
gDNA chr4:g.152328299G>A
cDNA c.1327C>T
Protein p.L443F
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_047415901.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
NM_033632.3 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_024454122.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_011532085.2 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_011532085.3 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_011532084.2 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_024454123.2 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_011532084.3 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_024454124.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
NM_001349798.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_024454123.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_047415899.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_047415900.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
NM_033632.3 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
NM_001349798.2 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_047415897.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_024454121.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38
XM_047415898.1 chr4:g.152328299G>A c.1327C>T p.L443F RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FBXW7 inact mut hematologic cancer sensitive Belinostat Preclinical Actionable In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut breast cancer sensitive Sirolimus Preclinical - Cell line xenograft Actionable In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170). 18787170
FBXW7 inact mut Advanced Solid Tumor sensitive Entinostat Preclinical Actionable In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut Advanced Solid Tumor resistant Docetaxel Preclinical Actionable In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910). 23274910
FBXW7 inact mut Advanced Solid Tumor sensitive Belinostat Preclinical Actionable In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut hematologic cancer sensitive REC-2282 Preclinical Actionable In a preclinical study, REC-2282 (AR-42) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut Advanced Solid Tumor sensitive REC-2282 Preclinical Actionable In a preclinical study, REC-2282 (AR-42) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 inact mut hematologic cancer sensitive Entinostat Preclinical Actionable In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
FBXW7 mutant Her2-receptor negative breast cancer predicted - sensitive LY3039478 Case Reports/Case Series Actionable In a Phase I trial, LY3039478 treatment resulted in partial response lasted 9.5 months in a patient with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FBXW7 mutation (PMID: 30060061; NCT01695005). 30060061